ライフサイエンスコーパス: beta-catenin

1 g growth factor-beta) and immunostaining for beta catenin.

2 in AJ formation through its interaction with beta-catenin.

3 hich resulted in the nuclear localization of beta-catenin.

4 hways, including Prlr/Stat5, TGFbeta and Wnt/beta-catenin.

5 accumulation is also capable of inducing Wnt/beta-catenin.

6 ysis of Axin and consequent stabilization of beta-catenin.

7 absence of crosstalk between TGFbeta and Wnt/beta-catenin.

8 hways, as well as increased total and active beta-catenin.

9 nd Tyr(86) in the N-terminal domain (NTD) of beta-catenin.

10 cular endothelial cadherin (VE-cadherin) and beta-catenin.

11 ncanonical Wnt signals by compartmentalizing beta-catenin.

12 ay activates the transcriptional activity of beta-catenin.

13 genes, and prevented nuclear accumulation of beta-catenin.

14 family kinase (SFK) FYN as well as Tyr142 in beta-catenin.

15 f ATX regulated expression of ATX as well as beta-catenin.

16 ta12,14-prostaglandin J2) decrease levels of beta-catenin.

17 is induced by Wnt signaling and conferred by beta-catenin.

18 own of IRE1alpha repressed the expression of beta-catenin, a key factor that drives colonic tumorigen

19 ss of Jak3-mediated phosphorylation sites in beta-catenin abrogated its AJ localization and compromis

20 SUMOylated beta-catenin accumulates at the chromatin and activates

21 ing that blocking PI3K-AKT pathway-dependent beta-catenin accumulation may represent a potential ther

22 Local injection of sFRP-2 attenuated the beta catenin activation and fibrosis.

23 Immunostaining revealed beta catenin activation and molecular studies revealed 1

24 bone marrow microenvironment, which lead to beta-catenin activation and disease progression of MDS.

25 XIN1, leading to impairment of WNT3a-induced beta-catenin activation and reduced Fgf18 expression in

26 osis through suppression of p53 and enhances beta-catenin activation and tumor proliferation.

27 eroids and colonoid cultures and TNF-induced beta-catenin activation in nontransformed human NCM460 c

28 Increased Wnt/beta-catenin activity in CNS blood vessels during EAE pr

29 These results reveal that APC-regulated beta-catenin activity in cortical progenitors sets the a

30 these mechanisms and the effects of SPDEF on beta-catenin activity in mouse models of colorectal canc

31 ssion was observed to reduce measures of Wnt/beta-catenin activity in osteocytes in the loaded bone.

32 increase load-induced bone formation and Wnt/beta-catenin activity in osteocytes.

33 ic role for Ror2 in regulating canonical Wnt/beta-catenin activity in vivo, where lentiviral shRNA de

34 ithin the developing kidney, tissue-specific beta-catenin activity is regulated by cooperation with c

35 Activation of WNT/beta-catenin activity with 6-bromoindirubin-3'-oxime imp

36 e to Lys05 and could be reverted by inducing beta-catenin activity.

37 in vitro and in vivo, along with reduced WNT/beta-catenin activity.

38 pathway, but rather by reductions in Akt and beta-catenin activity.

39 both the endoderm and mesoderm, whereas Wnt/beta-catenin acts as a genome-wide toggle between foregu

40 many processes that the Wnt pathway governs, beta-catenin acts primarily on a single cis element in t

41 G2 and Huh-6 xenografts showed expression of beta-catenin, AFP, and Glypican-3 (GPC3).

42 ted with cardiac fibroblast-specific loss of beta-catenin after trans-aortic constriction in vivo.

43 Activation of beta-catenin alone results in the formation of highly cl

44 TGF-beta-induced beta-catenin also regulates NR4A1 expression through for

45 iting EGFR-inhibitor response, including WNT/beta-catenin alterations and cell-cycle-gene (CDK4 and C

46 lyposis coli (APC) regulates the activity of beta-catenin, an integral component of Wnt signaling.

47 ound GC receptor, followed by stimulation of beta-catenin and c-myc pathways.

48 n, Gnas(+/p-) cells showed diminished pCREB, beta-catenin and cyclin D1, and enhanced Nfatc1 levels,

49 nants responsible for Jak3 interactions with beta-catenin and determine the functional implications o

50 ctions between ORF2 and a complex containing beta-catenin and HMGA1 have functional significance.

51 in latently infected neurons interacted with beta-catenin and HMGA1 in transfected cells, which resul

52 king the interaction of the protein CBP with beta-Catenin and inhibiting Wnt-activated genes.

53 s with Notch intracellular domain (NICD) and beta-catenin and is required for Ang1-dependent beta-cat

54 bp2(+/-) polyps exhibiting reduced levels of beta-catenin and its oncogenic transcriptional target, c

55 Moreover, NP12 increased the expression of beta-catenin and Nanog in myocardium from AMI mice.

56 This cleavage event occurs between the beta-catenin and p120-binding domains within the cadheri

57 gested a regulatory circuit between miR-152, beta-catenin and PKM2 in breast cancer.

58 ssion levels were negatively correlated with beta-catenin and PKM2 levels in breast cancer tissues.

59 is work suggests that GLI2 is a regulator of beta-catenin and provides insights into its role in tumo

60 Unexpectedly, beta-catenin and Smad1 binding were associated with both

61 observations are consistent with the role of beta-catenin and SNAIL in epidermal stem cell maintenanc

62 beta-catenin and Snail1 expression was generally high in

63 Specific molecular subgroup of HCA with beta-catenin and sonic hedgehog activation associated wi

64 ), we found evidence for the NREs binding to beta-catenin and Tcf-suggesting a dual action by beta-ca

65 gh downregulating multiple inhibitors of Wnt/beta-catenin and TGF-beta pathways, leading to their ove

66 ty of DPN harbor activating mutations in the beta-catenin and the MAP-kinase pathways; this character

67 associated with high co-expression of SCD1, beta-catenin and the YAP/TAZ downstream target birc5.

68 NB1 mutations have heterogeneous staining of beta-catenin and variable expression of gonadal receptor

69 ansgenic mice inducibly expressing oncogenic beta-catenin and/or PIK3CA(H1047R) to follow sequential

70 on, SMAD7 degradation, EMT, and induction of beta-catenin, and all of these pathways are inhibited by

71 with increased expression of E-cadherin and beta-catenin, and decreased expression of vimentin and s

72 Here, we have reported that the Hippo, Wnt/beta-catenin, and Notch pathways form an interacting net

73 nscription regulator 1 (YAP/TAZ), STAT3, Wnt/beta-catenin, and Notch signaling.

74 ified more key molecules (including Osterix, beta-catenin, and sonic hedgehog) that play a critical r

75 t abundance and activity, stabilizes nuclear beta-catenin, and stimulates canonical Wnt signaling mor

76 em, we verify that MAPK1, CDK1, CDK4, PRMT5, beta-catenin, and UbxD8 are directly ubiquitinated by E6

77 er cell types/organ systems in which Myc and beta-catenin are co-expressed.

78 cadherin, which releases cadherin-associated beta-catenin (Armadillo in Drosophila) and p120-catenin

79 In this study, we identified beta-catenin as a new direct target of miR-152.

80 These data established Wnt/beta-catenin as a novel signal produced by infiltrating

81 -catenin and Tcf-suggesting a dual action by beta-catenin as a signal and a feedforward sensor.

82 on of mutations in CTNNB1, the gene encoding beta-catenin, as a cause of FEVR.

83 DDB2 recruited EZH2 and beta-catenin at an upstream site in the Rnf43 gene, enab

84 Overexpression of KCNQ1 trapped beta-catenin at the plasma membrane, induced a patent lu

85 -protein interactions, bromodomains, and the beta-catenin/B-cell lymphoma 9 (BCL9) interaction were u

86 The two beta-catenin/BCL9 inhibitors had low nonspecific binding

87 P) isolated from AhR-/- livers had increased beta-catenin (beta-Cat) signaling with overexpression of

88 SPDEF disrupted beta-catenin binding to TCF1 and TCF3, displacing beta-c

89 ing functional interaction with distant TCF4/beta-catenin-binding sites in the intron of Rnf43 This n

90 imultaneously coordinates the attenuation of beta-catenin, both of which are required to execute the

91 proliferation because of dysregulation of a beta-catenin/BRN2 transcriptional cascade.

92 ations in APC that disrupt the regulation of beta-catenin by GSK-3beta cause colorectal cancer in hum

93 Removal of beta-catenin causes MMPs to favor adipogenesis, resultin

94 Analyzing beta-catenin ChIP sequencing in human cells, we found th

95 VEC/beta-catenin complex also sequesters a core subunit of P

96 that TGF-beta1 stimulation increases active beta-catenin concentration in cultured corneal fibroblas

97 These results indicate that decreased WNT/beta-catenin contributes to the pathophysiology of LMNA

98 tenin target gene Fam19a5 shows that Myc and beta-catenin cooperate to activate gene expression contr

99 Here, we show that beta-catenin cooperates with the transcription factor My

100 modulates CSF-1-dependent proliferation and beta-catenin/cyclinD1 levels in OC precursors.

101 1a/b, to facilitate the nuclear transport of beta-catenin, defining a parallel nuclear transport path

102 Wnt3a and SB216763 in order to activate the beta-catenin-dependent canonical Wnt pathway.

103 istinctions in the topology of canonical Wnt beta-catenin-dependent signaling activity and non-canoni

104 d the self-renewal of stem cells by inducing beta-catenin-dependent signalling through the Wnt recept

105 y enhanced the ability of HMGA1 to stimulate beta-catenin-dependent transcription, suggesting that in

106 r (TCF) reporter assays as a readout for Wnt/beta-catenin-dependent transcription.

107 Induction of GLI2DeltaN enhanced the beta-catenin-dependent transcriptional activation and th

108 developing kidney, Wnt9b regulates distinct beta-catenin-dependent transcriptional programs in the r

109 po1), an extracellular protein that enhances beta-catenin-dependent Wnt signaling and has previously

110 nuclear YAP/TAZ requires inactivation of the beta-catenin destruction complex.

111 factor responsible for the formation of the beta-catenin destruction complex.

112 ed lung function, and restored expression of beta-catenin-driven target genes and alveolar epithelial

113 Thus, we reported a novel crosstalk of ARF/beta-catenin dysregulated YAP in Hippo pathway and a new

114 denomas, linked to increased epithelial cell beta-catenin dysregulation.

115 Phosphorylation compartmentalizes Daple/beta-catenin/E-cadherin complexes to cell-cell contact s

116 tor complex for long-distance trafficking of beta-catenin/E-cadherin complexes to pericentriolar recy

117 nib: both reduced ROS-induced degradation of beta-catenin/E-cadherin in vitro and ameliorated skin da

118 vation of Src/Abl kinases and degradation of beta-catenin/E-cadherin.

119 , Axin1-beta-catenin interaction is lost and beta-catenin escapes ubiquitylation-dependent proteasoma

120 d subcellular localization pattern: Although beta-catenin exhibited a perinuclear pattern in undiffer

121 st effective at reducing average tumor size, beta-catenin expression levels, and the number of aberra

122 (BOS MCs) demonstrated constitutive nuclear beta-catenin expression that was dependent on autocrine

123 In tumor cells with activated beta -catenin, expression of SPDEF induced a quiescent s

124 eracted with beta-catenin, the NTD domain of beta-catenin facilitated its interactions with Jak3.

125 catenin binding to TCF1 and TCF3, displacing beta-catenin from enhancer regions of genes that regulat

126 , followed by phosphorylation of and loss of beta-catenin from the nucleus, thereby reducing expressi

127 ock-down of KCNQ1 caused a relocalization of beta-catenin from the plasma membrane and a loss of epit

128 s in beta-catenin that are required for full beta-catenin function.

129 ey nodes of this pathway through a series of beta-catenin gain-of-function (GSK3 inhibition and beta-

130 its aberrant beta-catenin nuclear signaling, beta-catenin haploinsufficiency induced aggressive tumor

131 While beta-catenin has been demonstrated as an essential molec

132 rmt1 as a key common downstream mediator for beta-catenin/Hoxa9 functions in LSK-derived MLL-CSCs.

133 reveal a novel molecular network mediated by beta-catenin/Hoxa9/Prmt1 in governing leukemic self-rene

134 triggers the mechanosensitive activation of beta-catenin in adjacent epidermal cells, initiating the

135 Constitutive activation of beta-catenin in hematopoietic cells yielded lethal myelo

136 dence that ORF2 was relocalized by HMGA1 and beta-catenin in Neuro-2A cells.

137 c accumulation and nuclear relocalization of beta-catenin in vitro and in 3D organotypic cultures, ac

138 in of E-Cadherin is essential for binding to beta-Catenin in vitro In cultured cells, phosphorylation

139 pendent signaling activity and non-canonical beta-catenin-independent Ror2-mediated Wnt signaling acr

140 gin predicts AML patient survival and allows beta-catenin-independent transformation in MLL-CSCs deri

141 omotes angiogenesis in HCCs by enhancing Wnt/beta-catenin induced FGF18 expression.

142 es downstream of LRP6, including JNK and WNT/beta-catenin, inhibited the biologic activity of domain

143 bitor 4mu8C could suppress the production of beta-catenin, inhibited the proliferation of colon cance

144 of Hoxa9 sensitizes LSK-derived MLL-CSCs to beta-catenin inhibition resulting in abolishment of CSC

145 Wnt/beta-catenin inhibition with Dkk-1 prevented the P-induc

146 long isoforms containing a unique N-terminal beta-catenin-interacting domain.

147 of SENP7S in mammary epithelial cells, Axin1-beta-catenin interaction is lost and beta-catenin escape

148 These data indicate that Tcf1-beta-catenin interaction is necessary for promoting thym

149 atenin levels and define PKC as an important beta-catenin interaction partner and signaling opponent

150 isoforms in mice (p45(-/-)mice) to abrogate beta-catenin interaction.

151 w that part of the challenge in antagonizing beta-catenin is caused by its dual functionality as a ce

152 cancer stem cells and (ii) downregulation of beta-catenin is partially driving effects of Indomethaci

153 beta-Catenin is the main effector of the canonical Wnt p

154 APC deletion deregulates beta-catenin, leads to high Wnt tone, and disrupts Notch

155 stimulated RPE cells by down-regulating Wnt (beta-catenin, LEF1) and TGF-beta (Smad2/3, collagen type

156 identified a novel pathway for regulation of beta-catenin levels and define PKC as an important beta-

157 e ErbB2(KI) basal tumor model, modulation of beta-catenin levels had no appreciable impact on tumor o

158 osphorylation of GSK3beta, decreasing active beta-catenin levels in both cytoplasmic and nuclear frac

159 nt of the destruction complex that regulates beta-catenin levels.

160 uscle-specifying genes by modulating TCF and beta-catenin levels.

161 We show that beta-catenin loss of function in cardiac fibroblasts aft

162 Here, we conditionally induce beta-catenin loss of function in resident cardiac fibrob

163 MNA cardiomyopathy and that drugs activating beta-catenin may be beneficial in affected individuals.

164 fic DNA-binding protein DDB2 is critical for beta-catenin-mediated activation of RNF43, which restric

165 ppress GC growth through a novel SOCE/Ca(2+)/beta-catenin-mediated anti-proliferation of GC cells, wh

166 nvestigated the role of TNF signaling in Wnt/beta-catenin-mediated intestinal stem cell and progenito

167 ndicates that the maintenance of appropriate beta-catenin-mediated Wnt tone is necessary for the orde

168 ich leads to Ras activation, cooperates with beta-catenin mutants (S33Y, S45Y) to yield HCC in mice.

169 ant transcription factor networks, including beta-catenin, MYB, TWIST1, SOX7, GATA3 and GATA6.

170 cancer (ErbB2(KI)), which exhibits aberrant beta-catenin nuclear signaling, beta-catenin haploinsuff

171 ors and LRP5 and LRP6 co-receptors, enabling beta-catenin nuclear translocation and TCF/LEF-dependent

172 by interacting with other proteins, such as beta-catenin or SMAD3 to induce oncogenic WNT and TGFbet

173 umors with common CRC mutations such as APC, beta-catenin, or RNF43.

174 in estrogen receptor, progesterone receptor, beta-catenin, or vimentin expression between placebo and

175 ough in multiple contexts Myc is a target of beta-catenin, our characterization of a cell type-specif

176 Further, beta-catenin overexpression in PKC-deficient podocytes c

177 atenin gain-of-function (GSK3 inhibition and beta-catenin overexpression) or loss-of-function experim

178 Here we show that beta-catenin pathway activity and adult epithelial proge

179 s exhibited strongly decreased autocrine Wnt/beta-catenin pathway activity and reduced Wnt pathway-de

180 S2 overexpression in ACC cells inhibited Wnt/beta-catenin pathway activity by promoting beta-catenin

181 Mutations of the beta-catenin pathway change the phenotype of a common ne

182 se results implicate deregulation of the Wnt/beta-catenin pathway in CNS inflammation and suggest nov

183 Here we demonstrate that activity of the Wnt/beta-catenin pathway in fibroblast-like cells in the les

184 while esculetin significantly inhibited Wnt/beta-catenin pathway in vitro and in vivo.

185 progenitor-specific inactivation of the APC-beta-catenin pathway indicates that the maintenance of a

186 disease predict differing effects of the WNT/beta-catenin pathway on metastatic progression.

187 The Wnt/beta-catenin pathway plays a role in almost every facet

188 PTPRZ1 and Wnt8a, two core components of the beta-catenin pathway, is downregulated by clofibrate.

189 /mTORC1 signaling cascades, and also the WNT/beta-catenin pathway.

190 A, its catalytic subunit Calpha, and the Wnt/beta-catenin pathway.

191 iation and function through cAMP/PKA and Wnt/beta-catenin pathways.

192 s of previously unknown tyrosine residues on beta-catenin phosphorylated by Jak3.

193 t/beta-catenin pathway activity by promoting beta-catenin phosphorylation and degradation, it also in

194 the combined therapy, PAKs regulate JNK and beta-catenin phosphorylation and mTOR pathway activation

195 levant modality is effective in treatment of beta-catenin-positive, GS-positive HCCs.

196 s required for the expression of every Wnt9b/beta-catenin progenitor renewal target assessed as well

197 a-catenin and is required for Ang1-dependent beta-catenin recruitment at the Dll4 locus.

198 Mechanistically, beta-catenin regulates expression of downstream targets

199 des, attempts to develop therapies targeting beta-catenin remain challenging, and none of these targe

200 Remarkably, beta-catenin showed a reversed subcellular localization

201 show how allosteric binders may overcome the beta-catenin side effects associated with strong GSK-3be

202 nic features by activating the canonical Wnt/beta-catenin signal pathway.

203 n of Ror2 expression augmented canonical Wnt/beta-catenin signaling activity across multiple basal-li

204 d Wnt8a promoters, ultimately decreasing Wnt/beta-catenin signaling activity, which is associated wit

205 novo TBL1XR1 point mutation could alter Wnt/beta-catenin signaling activity.

206 ll4 and Vgll4-4A markedly suppressed YAP and beta-catenin signaling activity.

207 The hyperactivated Wnt/beta-catenin signaling acts as a switch to induce epithe

208 d validates that berberine indeed suppresses beta-catenin signaling and cell growth in colon cancer v

209 the influence of KCNQ1 expression on the Wnt/beta-catenin signaling and epithelial-to-mesenchymal tra

210 HH)/glioma-associated oncogene (GLI) and WNT/beta-catenin signaling are important events in the genes

211 ion, and the cell type-specific roles of Wnt/beta-catenin signaling as it relates to liver physiology

212 Particularly, it activates Wnt/beta-catenin signaling by directly targeting Wnt antagon

213 entine formation, exogenous elevation of Wnt/beta-catenin signaling can enhance tertiary dentine form

214 These tumors lack deregulation of APC/beta-catenin signaling components, which are crucial gat

215 TNF plays a beneficial role in enhancing Wnt/beta-catenin signaling during ulcer healing in IBD.

216 Wnt/beta-catenin signaling elicits context-dependent transcr

217 Aberrant regulation of WNT/beta-catenin signaling has a crucial role in the onset a

218 Recently elevated Wnt/beta-catenin signaling has been detected in sepsis.

219 ese results suggest that reactivation of Wnt/beta-catenin signaling in CNS vessels during EAE/MS part

220 ghlight the importance of Th17 cells and Wnt/beta-catenin signaling in HIV control and especially ide

221 ceptor 4 (LGR4) axis in driving aberrant Wnt/beta-catenin signaling in MM.

222 n the highly context-dependent nature of WNT/beta-catenin signaling in tumors is essential to achieve

223 tory function of Wise and also modulates Wnt/beta-catenin signaling independently of Wise.

224 Wnt/beta-catenin signaling induces expression of col12a1a/b

225 rare lethal malignancy in which aberrant Wnt/beta-catenin signaling is frequently detected.

226 ment and homeostasis, precise control of Wnt/beta-catenin signaling is in part achieved by secreted a

227 Wingless and INT-1 (WNT)/beta-catenin signaling is reduced in COPD; however, the

228 ukocyte adhesion, involvement of the Akt/WNT/beta-catenin signaling pathway and relevant phosphatases

229 function results in deregulation of the Wnt/beta-catenin signaling pathway causing overexpression of

230 Deregulation of the Wnt/beta-catenin signaling pathway drives the development of

231 ths showed an abnormal activation of the Wnt/beta-catenin signaling pathway in a subset of zona fasci

232 y, we investigated the molecular role of Wnt/beta-catenin signaling pathway in reparative dentinogene

233 The WNT/beta-catenin signaling pathway is a prominent player in

234 Despite the improved understanding of the beta-catenin signaling pathway over the past three decad

235 umulating evidence demonstrates that the Wnt/beta-catenin signaling pathway plays a dominant role in

236 gs are significant because the canonical Wnt/beta-catenin signaling pathway promotes neurogenesis and

237 In this review, we discuss the Wnt/beta-catenin signaling pathway, its role in cell-cell ad

238 thway that controls angiogenesis, the Norrin-beta-catenin signaling pathway.

239 er, AZD4547 downregulated RTK, mTOR, and Wnt/beta-catenin signaling pathways in premalignant mammary

240 anistically, T63 activated both BMPs and WNT/beta-catenin signaling pathways.

241 This suggests that Wnt/beta-catenin signaling plays no major role in the format

242 eem to be independent of its activity as Wnt/beta-catenin signaling regulator.

243 LGR5 potentiates WNT/beta-catenin signaling through its unique constitutive i

244 a suggest a model whereby Lrp4 modulates Wnt/beta-catenin signaling via interaction with Wnt ligands

245 ound osteoanabolic capacity of activated Wnt/beta-catenin signaling, but serum sclerostin levels in h

246 tential of melanoma cells in response to WNT/beta-catenin signaling, correlating with differing metab

247 through p38 MAPK regulation of canonical Wnt/beta-catenin signaling, increasing alpha-SMA, COL1, and

248 ate that Apcdd1, a negative regulator of Wnt/beta-catenin signaling, is expressed in retinal endothel

249 rp5/6 and is implicated in modulation of Wnt/beta-catenin signaling, presumably through its ability t

250 Most MMs display aberrant Wnt/beta-catenin signaling, which drives proliferation; howe

251 dentified LGR4 as a master controller of Wnt/beta-catenin signaling-mediated breast cancer tumorigene

252 ied by reduced cerebrovascular canonical Wnt-beta-catenin signaling.

253 rostin and Sfrp4 consistent with reduced Wnt/beta-catenin signaling.

254 h plasma levels of molecules involved in Wnt/beta-catenin signaling.

255 d-forward mechanism to achieve sustained Wnt/beta-catenin signaling.

256 a axis, but contributed to the activation of beta-catenin signalling for the control of PD-1 and TNF

257 -barrier defects caused by impaired vascular beta-catenin signalling in mice.

258 healthy individuals to study the role of Wnt-beta-catenin signalling in myogenic differentiation.

259 LMNA cardiomyopathy, suggested decreased WNT/beta-catenin signalling.

260 Only some of the early dorsal beta-catenin signature genes were activated at blastula

261 In contrast, a slight activation of beta-catenin significantly increased bone formation and

262 y formation, cell motility and expression of beta-catenin, Snail, Slug, Zeb1 and N-cadherin, and upre

263 The beta-catenin-Snail1-Twist transcription factor cluster i

264 The transcription factor clusters of beta-catenin/Snail1/Twist has been implicated in the pro

265 How beta-catenin stimulated these two distinct programs was

266 ologically, Jak3-mediated phosphorylation of beta-catenin suppressed EGF-mediated epithelial-mesenchy

267 beta-catenin suppression by a clinically relevant modali

268 f overall tumor burden, were not affected by beta-catenin suppression.

269 uence of repression of the KCNQ1 promoter by beta-catenin:T-cell factor (TCF)-4.

270 s demonstrated by studies of TNF-induced Wnt/beta-catenin target gene expression in murine enteroids

271 a cell type-specific enhancer for the Wnt9b/beta-catenin target gene Fam19a5 shows that Myc and beta

272 only provides insight into the regulation of beta-catenin target genes in the developing kidney, but

273 activation and the subsequent activation of beta-catenin target genes including cyclin-D1.

274 Upregulation of Wnt/beta-catenin target molecules in the optic cup and stalk

275 ch was associated with dramatic decreases in beta-catenin targets and some K-Ras effectors, leading t

276 -beta-catenin tumors showed up-regulation of beta-catenin targets like glutamine synthetase (GS), leu

277 es NR4A1 expression through formation of the beta-catenin-TCF-3/TCF-4/LEF-1 complex on the NR4A1 prom

278 Beta-catenin/Tcf and the TGF-beta bone morphogenetic pro

279 These studies support the role of SATB2/beta-catenin/TCF-LEF pathway in transformation and carci

280 hways represented by these mRNAs include Wnt/beta-catenin, TGF-beta, and stem cell signaling.

281 nction mutations in the CTNNB1 gene encoding beta-catenin that also activate canonical WNT signaling.

282 three PKC-specific phosphorylation sites in beta-catenin that are required for full beta-catenin fun

283 and moesin) domains of Jak3 interacted with beta-catenin, the NTD domain of beta-catenin facilitated

284 nctions by AJ localization of phosphorylated beta-catenin through its interactions with alpha-catenin

285 , prevent increases in both total and active beta-catenin through p38 MAPK-GSK3beta signaling.

286 adipocyte defects caused by up-regulation of beta-catenin transcriptional activities.

287 K-Ras-beta-catenin tumors showed up-regulation of beta-catenin

288 e shown that coexpression of hMet and mutant-beta-catenin using sleeping beauty transposon/transposas

289 In the present study, beta-catenin was activated at different levels or delete

290 The pivotal role of beta-catenin was further indicated by the up-regulation

291 ng step during Jak3 trans-phosphorylation of beta-catenin, where Jak3 directly phosphorylated three t

292 egulation may promote beta-oxidation through beta-catenin, whereas hypertrophy was dependent on mamma

293 pression of Wnt5A, an intrinsic inhibitor of beta-catenin, which also promotes invasion.

294 Signal in the pathway is transduced by beta-catenin, which in complex with Tcf/Lef regulates tr

295 m of PKC and a well-known binding partner of beta-catenin, which promotes its degradation.

296 tor-4alpha was associated with activation of beta-catenin, which regulates liver zonation.

297 ivin to induce Wnt3 expression and stabilize beta-catenin, which then synergizes with Activin-induced

298 esults in nuclear export of TGF-beta-induced beta-catenin, which then undergoes proteasome-dependent

299 of the culture system, IWP2 decreased total beta-catenin while CHIR99021 increased it in nuclear loc

300 phosphorylated Jak3 bound to phosphorylated beta-catenin with a dissociation constant of 0.28 mum, a

301 erve that high co-expression levels of SCD1, beta-catenin, YAP/TAZ and downstream targets have a stro